MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares U.S. Pharmaceutical ETF (NY:IHE)

100.51 -1.71 (-1.67%)
Official Closing Price Updated: 8:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,043,524
Open 102.11
Bid (Size) 99.88 (3,000)
Ask (Size) 101.30 (3,000)
Prev. Close 102.22
Today's Range 99.97 - 102.39
52wk Range 64.94 - 103.70
Shares Outstanding 82,000
Dividend Yield 1.13%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗
Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years. 
Via The Motley Fool
Topics ETFs
News headline image
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors? ↗
Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs. 
Via The Motley Fool
Topics ETFs Intellectual Property

Performance

YTD
+18.4%
+18.4%
1 Month
+5.7%
+5.7%
3 Month
+15.0%
+15.0%
6 Month
+17.3%
+17.3%
1 Year
+49.6%
+49.6%

More News

Read More
News headline image
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗
Via The Motley Fool
Topics ETFs
KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show? ↗
Via Stocktwits
Why Did NRXP Stock Surge 21% Pre-Market Today? ↗
Via Stocktwits
White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗
Via Stocktwits
News headline image
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns ↗
Via The Motley Fool
Topics ETFs
News headline image
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game. ↗
Via The Motley Fool
Topics ETFs
News headline image
FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report ↗
Via Stocktwits
News headline image
TBPH Stock Slumps 30%, Falls Below 200-DMA For First Time In Over 9 Months As Phase 3 Study Misses Primary Endpoint ↗
Via Stocktwits
Topics Workforce
News headline image
FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development ↗
Via Stocktwits
Topics ETFs Government
News headline image
Why Did IINN Stock Surge 28% In Pre-Market Today? ↗
Via Stocktwits
News headline image
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗
Via Stocktwits
Topics Intellectual Property
News headline image
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗
Via Stocktwits
News headline image
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗
Via Stocktwits
Topics World Trade
News headline image
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗
Via Benzinga
Topics ETFs
News headline image
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗
Via Benzinga
News headline image
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗
Via Benzinga
Topics ETFs
News headline image
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
Via Benzinga
Topics ETFs
News headline image
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗
Via Benzinga
Topics Government World Trade
News headline image
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗
Via Benzinga
News headline image
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗
Via Benzinga
News headline image
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' ↗
Via Benzinga
News headline image
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗
Via Benzinga
Topics Artificial Intelligence ETFs
News headline image
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗
Via Benzinga
Topics Government World Trade

Frequently Asked Questions

Is iShares U.S. Pharmaceutical ETF publicly traded?
Yes, iShares U.S. Pharmaceutical ETF is publicly traded.
What exchange does iShares U.S. Pharmaceutical ETF trade on?
iShares U.S. Pharmaceutical ETF trades on the New York Stock Exchange
What is the ticker symbol for iShares U.S. Pharmaceutical ETF?
The ticker symbol for iShares U.S. Pharmaceutical ETF is IHE on the New York Stock Exchange
What is the current price of iShares U.S. Pharmaceutical ETF?
The current price of iShares U.S. Pharmaceutical ETF is 100.51
When was iShares U.S. Pharmaceutical ETF last traded?
The last trade of iShares U.S. Pharmaceutical ETF was at 07/10/26 08:00 PM ET
What is the market capitalization of iShares U.S. Pharmaceutical ETF?
The market capitalization of iShares U.S. Pharmaceutical ETF is 8.24M
How many shares of iShares U.S. Pharmaceutical ETF are outstanding?
iShares U.S. Pharmaceutical ETF has 8M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story